Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own ...

Pfizer, despite pressure from investors to look outside, elevates its cancer chief Chris Boshoff to lead overall R&D.

The drug company had been searching for a new chief scientific officer since July with Mikael Dolsten leaving after 15 years ...

Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.

As for his soon-to-be former role, Boshoff will be succeeded by Dr. Roger Dansey, who will serve as the interim chief ...

Chris Boshoff will take over as Pfizer’s next chief scientific officer as of January 1, replacing Mikael Dolsten who led the ...

"Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a world-leading organisation with ...

Pfizer has appointed company insider Chris Boshoff as its new chief scientific officer, the US drugs giant confirmed on ...

Pfizer (PFE) announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, ...

Boshoff replaces Mikael Dolsten, who led research and development at the drug giant for 15 years and who announced his plans to retire in July. The news may disappoint some investors, who may have ...

Replaces Mikael Dolsten (Il Sole 24 Ore Radiocor) - New York, 20 Nov - The US pharmaceutical Pfizer said that it has appointing Chris Boshoff as chief scientific officer and president in charge of ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Pfizer on Wednesday said it will promote Chris ...